SEPS Pharma is a privately held pharmaceutical company with a hybrid business model engaged in drug delivery and development. The company applies the combination of carefully designed prodrugs with the appropriate delivery forms creating innovative therapies for patients by expanding the medical application field of existing and well-characterised drugs, initially targeted to the following therapeutic areas: infectious diseases (antiviral, antifungal, antibacterial), oncology, migraine, chemotherapy-induced and postoperative nausea vomiting. The edge of the company resides in the fact that SEPS Pharma is developing variants of highly selling drugs, including blockbusters, for a second 'patent life protected' period with substantial improvements over the initial parent drug.

In addition, SEPS Pharma provides advanced drug product development services to the leading pharmaceutical and biotechnology companies. The company offers a full suite of drug development services encompassing preclinical development, preformulation development, formulation development, dosage forms development and scaling-up of small molecules and biopharmaceuticals for oral, pulmonary, nasal and parenteral delivery.